Serum soluble CD44 levels for monitoring disease states in acute leukemia and myelodysplastic syndromes

International Journal of Oncology

Volumn 13, Issue 3, 1998, Pages 525-530

  Nasu, Hidekazu ^a   Hibi, Nozomu ^a   Ohyashiki, Junko H ^b   Hara, Akinori ^a   Kubono, Katsuo ^a   Tsukada, Yutaka ^a   Ando, Keiko ^b   Iwama, Hiroshi ^b   Hayashi, Shigefumi ^b   Yahata, Naoyuki ^b   Toyama, Keisuke ^b   Ohyashiki, Kazuma ^b  

^a SRL INC   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Hematologic neoplasia; Soluble CD44

Indexed keywords

ANTINEOPLASTIC AGENT; HERMES ANTIGEN; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PATIENT MONITORING; PRIORITY JOURNAL;

EID: 13144281706     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.3.525     Document Type: Article

References (28)

1. Haynes BF, Telen MJ, Hale LP and Denning SM: CD44 - a molecule involved in leukocyte adherence and T-cell activation. Immunol Today 10:423-428, 1989.
2. Aruffo A, Stamenkovic I, Melnick M, Underbill CB and Seed B: CD44 is the principal cell surface receptor for hyaluronate. Cell 61: 1303-1313, 1990.
3. Miyake K, Underhill CB, Lesley J and Kincade PW: Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med 172: 69-75, 1990.
4. Carter WG and Wayner EA: Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. J Biol Chem 263: 4193-4201, 1988.
5. Jalkanen S, Bargatze RF, De Los Toyos J and Butcher EC: Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J Cell Biol 105: 983-990, 1987.
6. Miyake K, Medina KL, Hayashi S, Ono S, Hamaoka T and Kincade PW: Monoclonal antibodies to Pgp-1/CD44 block lympho-hemopoiesis in long-term bone marrow cultures. J Exp Med 171: 477-488, 1990.
7. Huet S, Groux H, Caillou B, Valentin H, Prieur AM and Bernard A: CD44 contributes to T cell activation. J Immunol 143: 798-801, 1989.
8. Shimizu Y, van Seventer GA, Siraganian R, Wahl L and Shaw S: Dual role of the CD44 molecule in T cell adhesion and activation. J Immunol 143: 2457-2463, 1989.
9. St. John T, Meyer J, Idzerda R and Gallatin WM: Expression of CD44 confers a new adhesive phenotype on transfected cells. Cell 60: 45-52, 1990.
10. Jackson DG, Buckley J and Bell JI: Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J Biol Chem 267: 4732-4739, 1992.
11. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U and Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89: 12160-12164, 1992.
12. Matsumura Y and Tarin D: Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 340: 1053-1058, 1992.
13. Tanabe KK, Ellis LM and Saya H: Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 341: 725-726, 1993.
14. Heider KH, Hofmann M, Hors E, van den Berg F, Ponta H, Herrlich P and Pals ST: A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 120: 227-233, 1993.
15. Mulder JW, Kruyt PM, Sewnath M, Costing J, Seldenrijk CA, Weidema WF, Offerhaus GJ and Pals ST: Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 344: 1470-1472, 1994.
16. Mayer B, Jauch KW, Gunthert U, Figdor CG, Schildberg FW, Funke I and Johnson JP: De novo expression of CD44 and survival in gastric cancer. Lancet 342: 1019-1022, 1993.
17. Iida N and Bourguignon LY: New CD44 splice variants associated with human breast cancers. J Cell Physiol 162: 127-133, 1995.
18. Dali P, Heider KH, Sinn HP, Skroch-Angel P, Adolf G, Kaufmann M, Herrlich P and Ponta H: Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer 60: 471-477, 1995.
19. Lucas MG, Green AM and Telen MJ: Characterization of the serum In(Lu)-related antigen: identification of a serum protein related to erythrocyte p80. Blood 73: 596-600, 1989.
20. Haynes BF, Hale LP, Patton KL, Martin ME and McCallum RM: Measurement of an adhesion molecule as an indicator of inflammatory disease activity. Up-regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis Rheum 34: 1434-1443, 1991.
21. Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J and Sy MS: Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 54: 422-426, 1994.
22. Kan M, Kanayama H, Naruo S, Tsuji M, Kojima K, Kurokawa Y and Kagawa S: Serological evaluation of soluble CD44 in renal cancer. Jpn J Cancer Res 87: 1191-1194, 1996.
23. Ristamaki R, Joensuu H, Salmi M and Jalkanen S: Serum CD44 in malignant lymphoma: an association with treatment response. Blood 84: 238-243, 1994.
24. De Rossi G, Marroni P, Paganuzzi M, Mauro FR, Tenca C, Zarcone D, Velardi A, Molica S and Grossi CE: Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia 11: 134-141, 1997.
25. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposed revised criteria for the classification of acute myeloid leukemia. A report of the FrenchAmerican-British Cooperative Group. Ann Intern Med 103: 620-625, 1985.
26. Harlow E and Lane D: Monoclonal antibodies. In: Antibodies. A Laboratory Manual. Cold Spring Harbor Laboratory, New York, pp139-243, 1988.
27. Bazil V and Horejsi V: Shedding of the CD44 adhesion molecule from leukocytes induced by anti-CD44 monoclonal antibody simulating the effect of a natural receptor ligand. J Immunol 149: 747-753, 1992.
28. Ristamaki R, Joensuu H, Gron-Virta K, Salmi M and Jalkanen S: Origin and function of circulating CD44 in non-Hodgkin's lymphoma. J Immunol 158: 3000-3008, 1997.